Science News

Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster.

A new interesting article has been published in Drugs Aging. 2018 Dec;35(12):1031-1040. doi: 10.1007/s40266-018-0603-x. and titled:

Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster.

Authors of this article are:

Syed YY.

A summary of the article is shown below:

Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years. In the pivotal trials in adults aged ≥ 50 years (ZOE-50) and ≥ 70 years (ZOE-70), RZV significantly reduced the risk of HZ and PHN. Its protective efficacy waned minimally over 4 years and was well preserved in adults aged ≥ 70 years. In patients with breakthrough disease, RZV reduced HZ-related pain severity, burden of illness and burden of interference with activities of daily living. RZV was more reactogenic than placebo, with injection-site reactions, myalgia and fatigue being the most common solicited adverse reactions. However, most solicited adverse reactions were transient and were mild to moderate in severity. RZV represents a novel, highly effective and well-tolerated vaccine option for HZ and PHN in adults aged ≥ 50 years. RZV is not contraindicated in immunocompromised individuals, and is preferred over a live attenuated HZ vaccine in immunocompetent individuals, according to the US and Canadian guidelines.

Check out the article’s website on Pubmed for more information:

This article is a good source of information and a good way to become familiar with topics such as:



Categories: Science News